Novartis AG vs Target Corporation — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Target Corporation trades at $138.64 (market cap $63.40B). The key difference: Novartis AG is far larger — about 4.6× Target Corporation's market cap, and Target Corporation pays the higher dividend (3.32%). Which is the better fit depends on your goals.
| NVS | TGT | |
|---|---|---|
Market Cap | $290.25B | $63.40B |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $141.19 |
52-Week Low | $113.50 | $83.68 |
Enterprise Value | $330.27B | $78.70B |
Dividend Yield | 3.17% | 3.32% |
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →